779 related articles for article (PubMed ID: 26529078)
41. Bile duct proliferation associated with bile salt-induced hypercholeresis in Mdr2 P-glycoprotein-deficient mice.
Hulzebos CV; Voshol PJ; Wolters H; Kruit JK; Ottenhof R; Groen AK; Stellaard F; Verkade HJ; Kuipers F
Liver Int; 2005 Jun; 25(3):604-12. PubMed ID: 15910498
[TBL] [Abstract][Full Text] [Related]
42. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
[TBL] [Abstract][Full Text] [Related]
43. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders.
Karpen SJ; Kelly D; Mack C; Stein P
Hepatol Int; 2020 Sep; 14(5):677-689. PubMed ID: 32653991
[TBL] [Abstract][Full Text] [Related]
44. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
45. Bile acid transporters: structure, function, regulation and pathophysiological implications.
Alrefai WA; Gill RK
Pharm Res; 2007 Oct; 24(10):1803-23. PubMed ID: 17404808
[TBL] [Abstract][Full Text] [Related]
46. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
47. Impact of Inhibiting Ileal Apical versus Basolateral Bile Acid Transport on Cholesterol Metabolism and Atherosclerosis in Mice.
Dawson PA
Dig Dis; 2015; 33(3):382-7. PubMed ID: 26045273
[TBL] [Abstract][Full Text] [Related]
48. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation.
Geuken E; Visser D; Kuipers F; Blokzijl H; Leuvenink HG; de Jong KP; Peeters PM; Jansen PL; Slooff MJ; Gouw AS; Porte RJ
J Hepatol; 2004 Dec; 41(6):1017-25. PubMed ID: 15582136
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic potential of berberine in attenuating cholestatic liver injury: insights from a PSC mouse model.
Wang Y; Zhao D; Su L; Tai YL; Way GW; Zeng J; Yan Q; Xu Y; Wang X; Gurley EC; Zhou XQ; Liu J; Liu J; Chen W; Hylemon PB; Zhou H
Cell Biosci; 2024 Jan; 14(1):14. PubMed ID: 38273376
[TBL] [Abstract][Full Text] [Related]
50. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
51. Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
Hegade VS; Jones DE; Hirschfield GM
Dig Dis; 2017; 35(3):267-274. PubMed ID: 28249258
[TBL] [Abstract][Full Text] [Related]
52. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
Zhuang Y; Ortega-Ribera M; Thevkar Nagesh P; Joshi R; Huang H; Wang Y; Zivny A; Mehta J; Parikh SM; Szabo G
Hepatology; 2024 Apr; 79(4):752-767. PubMed ID: 37725754
[TBL] [Abstract][Full Text] [Related]
53. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological inhibition of the ideal apical sodium-dependent bile acid transporter ASBT ameliorates cholestatic liver disease in mice.
Ghallab A
Arch Toxicol; 2019 Oct; 93(10):3039-3040. PubMed ID: 31542800
[No Abstract] [Full Text] [Related]
55. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
Kim YC; Jung H; Seok S; Zhang Y; Ma J; Li T; Kemper B; Kemper JK
Hepatology; 2020 Jun; 71(6):2118-2134. PubMed ID: 31549733
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of ileal bile acid absorption in bile-duct-ligated rats.
Sauer P; Stiehl A; Fitscher BA; Riedel HD; Benz C; Klöters-Plachky P; Stengelin S; Stremmel W; Kramer W
J Hepatol; 2000 Jul; 33(1):2-8. PubMed ID: 10905579
[TBL] [Abstract][Full Text] [Related]
57. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
58. Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys.
Kitayama K; Nakai D; Kono K; van der Hoop AG; Kurata H; de Wit EC; Cohen LH; Inaba T; Kohama T
Eur J Pharmacol; 2006 Jun; 539(1-2):89-98. PubMed ID: 16687134
[TBL] [Abstract][Full Text] [Related]
59. Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences.
Thomas C; Landrier JF; Gaillard D; Grober J; Monnot MC; Athias A; Besnard P
Gut; 2006 Sep; 55(9):1321-31. PubMed ID: 16484503
[TBL] [Abstract][Full Text] [Related]
60. Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor.
Zhang L; Shi J; Shen Q; Fu Y; Qi S; Wu J; Chen J; Zhang H; Mu Y; Chen G; Liu P; Liu W
J Ethnopharmacol; 2024 Jan; 318(Pt A):116833. PubMed ID: 37400008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
